Elsevier

Annals of Oncology

Volume 31, Issue 9, September 2020, Pages 1115-1118
Annals of Oncology

Editorial
The FDA approval of pembrolizumab for adult and pediatric patients with tumor mutational burden (TMB) ≥10: a decision centered on empowering patients and their physicians

https://doi.org/10.1016/j.annonc.2020.07.002Get rights and content
Under an Elsevier user license
open archive

Cited by (0)